Diagnosis of hepatocellular carcinoma

HPB

Volumn 7, Issue 1, 2005, Pages 26-34

  Bialecki, Eldad S ^a   Di Bisceglie, Adrian M ^a  

^a Saint Louis University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; DECARBOXYPROTHROMBIN;

ACCURACY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; EARLY DIAGNOSIS; ECHOGRAPHY; FREQUENCY ANALYSIS; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN BLOOD LEVEL; REVIEW;

EID: 15844412987     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1080/13651820410024049     Document Type: Review

References (111)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827-41.
2. Pal S, Pande GK. Current status of surgery and transplantation in the management of hepatocellular carcinoma: an overview. J Hepatobiliary Pancreat Surg 2001;8:323-36.
3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340:745-50.
4. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999;353:1253-7.
5. Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998;28:751-5.
6. Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 1999;19:311-22.
7. Torzilli G, Belghiti J, Makuuchi M. Differences and similarities in the approach to hepatocellular carcinoma between Eastern and Western institutions. Liver Transpl 2004; 10(2 Suppl 1):S1-S2.
8. Prorok PC. Epidemiologic approach for cancer screening. Problems in design and analysis of trials. Am J Pediatr Hematol Oncol 1992;14:117-28.
9. McMahon BJ, Bulkow L, Harpster AL, Snowball M, Lanier A, Sacco F, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000;32(4 Pt 1):842-6.
10. Mima S, Sekiya C, Kanagawa H, Kohyama H, Gotoh R, Mizuo H, et al, Mass screening for hepatocellular carcinoma: experience in Hokkaido, Japan. J Gastroenterol Hepatol 1994;9:361-5.
11. Tong MJ, Blatt LM, Kao VW. Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol 2001;16:553-9.
12. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001;48:251-9.
13. Pateron D, Ganne N, Trinchet JC, Aurousseau MH, Mal F, Meicler C, et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994;20:65-71.
14. Chalasani N, Said A, Ness R, Hoen H, Lumeng L. Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey. Am J Gastroenterol 1999;94:2224-9.
15. Koteish A, Thuluvath PJ. Screening for hepatocellular carcinoma. J Vasc Interv Radiol 2002;13(9 Pt2):S185-S190.
16. Di Bisceglie AM, Carithers RL Jr, Gores QJ. Hepatocellular carcinoma. Hepatology 1998;28:1161-5.
17. Lieberman DA. Cost-effectiveness model for colon cancer screening. Gastroenterology 1995;109:1781-90.
18. Bailey MA, Brunt EM. Hepatocellular carcinoma: predisposing conditions and precursor lesions. Gastroenterol Clin North Am 2002;31:641-62.
19. McMahon BJ. Hepatocellular carcinoma and viral hepatitis. In: Wilson RA, editor. Viral hepatitis: diagnosis, treatment, prevention. New York: Marcel Dekker; 1997. p 315-30.
20. Hillebrand DJ, Sandowski SA. Hepatobiliary disease. Hepatocellular carcinoma. Clin Fam Pract 2000;2:79-97.
21. Bosch FX. Global epidemiology of hepatocellular carcinoma. In: Okuda K, Tabor E, editors Liver cancer. New York: Churchill Livingstone; 1997. p 13-28.
22. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988;61:1942-56.
23. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-74.
24. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336:1855-9.
25. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998;75:347-54.
26. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31.
27. Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997;25:754-8.
28. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997;26(3 Suppl 1):2S-10S.
29. Miyakawa H, Sato C, Tazawa J, Izumi N, Hatton K, Ebata A, et al. A prospective study on hepatocellular carcinoma in liver cirrhosis: respective roles of alcohol and hepatitis C virus infection. Alcohol Alcohol 1994; 29(Suppl 1):75-9.
30. Stal P. Iron as a hepatotoxin. Dig Dis Sci 1995;13:205-22.
31. Kato Y, Nakata K, Omagari K, Furukawa R, Kusumoto Y, Mori I, et al. Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infectious hepatitis viruses. Cancer 1994;74:2234-8.
32. Benvegnu L, Fattovich G, Noventa F, Tremolada F, Chemello L, Ceccetto A, et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer 1994;74:2442-8.
33. Zaman SN, Melia WM, Johnson RD, Portmann BC, Johnson PJ, Williams R. Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients. Lancet 1985;1:1357-60.
34. Melia WM, Johnson PJ, Neuberger J, Zaman S, Portmann BC, Williams R. Hepatocellular carcinoma in primary biliary cirrhosis: detection by alpha-fetoprotein estimation. Gastroenterology 1984;87:660-3.
35. Ryder SD, Koskinas J, Rizzi PM, McFarlane IG, Portmann BC, Naoumov NV, et al. Hepatocellular carcinoma complicating autoimmune hepatitis: role of hepatitis C virus. Hepatology 1995;22:718-22.
36. Bralet MP, Regimbeau JM, Pineau P, Dubois S, Loas G, Degos F, et al. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology 2000;32:200-4.
37. Kashyap R, Join A, Nalesnik M, Carr B, Barnes J, Vargas HE, et al. Clinical significance of elevated alpha-fetoprotein in adults and children. Dig Dis Sci 2001;46:1709-13.
38. Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 2001;5:145-59.
39. Colombo M. Screening for cancer in viral hepatitis. Clin Liver Dis 2001;5:109-22.
40. Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med 2003;139:46-50.
41. Taketa K. Alpha-fetoprotein. J Med Technol 1989;33:1380.
42. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002; 122:1609-19.
43. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995; 22:432-8.
44. Johnson PJ, Poon TC, Hjelm NM, Ho CS, Ho SK, Welby C, et al. Glycan composition of serum alpha-fetoprotein in patients with hepatocellular carcinoma and non-semi-nomatous germ cell tumour. BrJ Cancer 1999;81:1188-95.
45. Shimizu K, Katoh H, Yamashita F, Tanaka F, Tanaka M, Tanikawa K, et al. Comparison of carbohydrate structures of serum alpha-fetoprotein by sequential glycosidase digestion and lectin affinity electrophoresis. Clin Chim Acta 1996;254:23-40.
46. Aoyagi Y, Suzuki Y, Isemura M, Nomoto M, Sekine C, Igarashi K, et al. The fucosylation index of alpha-fetoprotein and its usefulness in the early diagnosis of hepatocellular carcinoma. Cancer 1988;61:769-74.
47. Saitoh S, Ikeda K, Koida I, Suzuki Y, Kobayashi M, Tsubota A, et al. Diagnosis of hepatocellular carcinoma by concanavalin A affinity electrophoresis of serum alpha-fetoprotein. Cancer 1995;76:1139-44.
48. Taketa K, Endo Y, Sekiya C, Tanikawa K, Koji T, Taga H, et al. A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res 1993;53:5419-23.
49. Burditt LJ, Johnson MM, Johnson PJ, Williams R. Detection of hepatocellular carcinoma-specific alpha-fetoprotein by isoelectric focusing. Cancer 1994;74:25-9.
50. Johnson PJ, Leung N, Cheng P, Welby C, Leung WT, Lau WY, et al. 'Hepatoma-specific' alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease. Br J Cancer 1997;75:236-40.
51. Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984;310:1427-31.
52. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RL, et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003;37:1114-21.
53. Weitz IC, Liebman HA. Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology 1993;18:990-7.
54. Tanabe Y, Ohnishi K, Nomura F, Iida S. Plasma abnormal prothrombin levels in patients with small hepatocellular carcinoma. Am J Gastroenterol 1988;83:1386-9.
55. Nagaoka S, Yatsuhashi H, Hamada H, Yano K, Matsumoto T, Daikoku M, et al. The des-gamma-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma. Cancer 2003;98:2671-7.
56. Murakami T, Mochizuki K, Nakamura H. Imaging evaluation of the cirrhotic liver. Semin Liver Dis 2001;21:213-24.
57. Takayasu K, Moriyami N, Muramatsu Y, Makuuchi M, Hosegawa H, Okazaki N, et al. The diagnosis of small hepatocellular carcinomas: efficacy of various imaging procedures in 100 patients. AJR Am J Roentgenol 1990;155:49-54.
58. Chalasani N, Horlander JC Sr, Said A, Hoen H, Kopecky KK, Stockberger SM Jr, et al. Screening for hepatocellular carcinoma in patients with advanced cirrhosis. Am J Gastroenterol 1999;94:2988-93.
59. Di Bisceglie AM. Epidemiology and clinical presentation of hepatocellular carcinoma. J Vasc Interv Radiol 2002;13(9 Pt 2):S169-S171.
60. Murata K, Shiraki K, Kawakita. T, Yamamoto N, Okano H, Sakai T, et al. Hepatocellular carcinoma presenting with obstructive jaundice: a clinicopathological study of eight patients. Hepatogastroenterology 2003;50:2057-60.
61. Chen ZY, Qi QH, Dong ZL. Etiology and management of hemorrhage in spontaneous liver rupture: a case report of 70 cases. World J Gastroenterol 2002;8:1063-6.
62. Si MS. Prevalence of metastasis in hepatocellular carcinoma: risk factors and impact on survival. Am Surg 2003;69:879.
63. Luo JC. Clinical characteristics and prognosis of hepatocellular carcinoma patients with paraneoplastic syndromes. Hepatogastroenterology 2002;49:1315.
64. Bruix J, Castells A, Calvet X, Feu F, Bru C, Sole M, et al. Diarrhea as a presenting symptom of hepatocellular carcinoma. Dig Dis Sci 1990;35:681-5.
65. Steiner E, Velt P, Gutierrez O, Schwartz S, Chey W. Hepatocellular carcinoma presenting with intractable diarrhea. A radiologic-pathologic correlation. Arch Surg 1986; 121:849-51.
66. Ackerman D. Cutaneous metastasis from hepatocellular carcinoma. Int J Dermatol 2001;40:782.
67. Fracanzani AL. Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease. J Hepatol 2001;35:498.
68. Tangkijvanich P, Anukulkamkusol N, Suwangool P, Lertmaharit S, Hanvivatvong O, Kullavanijaya P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol 2000;31:302-8.
69. Hanazaki K, Kajikawa S, Koide N, Adachi W, Amano J. Prognostic factors after hepatic resection for hepatocellular carcinoma with hepatitis C viral infection: univariate and multivariate analysis. Am J Gastroenterol 2001; 96:1243-50.
70. Andorno E, Salizzoni M, Schieroni R, De Hemptinne B. Role of serum alpha-fetoprotein in pre- and post-orthotopic liver transplantation (OLT) for malignant disease. J Nucl Med Allied Sci 1989;33(3 Suppl):132-4.
71. Johnson PJ, Williams R. Serum alpha-fetoprotein estimations and doubling time in hepatocellular carcinoma: influence of therapy and possible value in early detection. J Natl Cancer Inst 1980;64:1329-32.
72. Urabe T, Hayashi S, Terasaki S, Terada M, Matsushita E, Kaneko S, et al. [An assessment of therapeutic effect of hepatocellular carcinoma by the serial changes in serum AFP value]. Nippon Shokakibyo Gakkai Zasshi 1990;87:100-8 [in Japanese].
73. Johnson PJ, Williams R, Thomas H, Sherlock S, Murray-Lyon IM. Induction of remission in hepatocellular carcinoma with doxorubicin. Lancet 1978;1:1006-9.
74. McIntire KR, Vogel CL, Primack A, Waldmann TA, Kyalwazi SK. Effect of surgical and chemotherapeutic treatment on alpha-fetoprotein levels in patients with hepatocellular carcinoma. Cancer 1976;37:677-83.
75. Choi BI, Kim AY, Lee JY, Kim KW, Lee KH, Kim TK, et al. Hepatocellular carcinoma: contrast enhancement with Levovist. J Ultrasound Med 2002;21:77-84.
76. Kubo S, Kinashita H, Hirohashi K, Tsukamoto T, Shuto T. Preoperative localization of hepatomas by sonography with microbubbles of carbon dioxide. AJR Am J Roentgenol 1994;163:1405-6.
77. 2 and helium microbubbles for detection of hepatocellular carcinoma: preliminary observations. Radiology 1998; 206:767-71.
78. Reinhold C, Hammers L, Taylor CR, Quedens-Case CL, Holland CK, Taylor KJ. Characterization of focal hepatic lesions with duplex sonography: findings in 198 patients. AJR Am J Roentgenol 1995;164:1131-5.
79. Tanaka S, Kitamura T, Fujita M, Nakanishi K, Okuda S. Color Doppler flow imaging of liver tumors. AJR Am J Roentgenol 1990;154:509-14.
80. Koito K, Namieno T, Morita K. Differential diagnosis of small hepatocellular carcinoma and adenomatous hyperplasia with power Doppler sonography. AJR Am J Roentgenol 1998;170:157-61.
81. Choi BI, Kim TK, Han JK, Chung JW, Park JH, Han MC. Power versus conventional color Doppler sonography: comparison in the depiction of vasculature in liver tumors. Radiology 1996;200:55-8.
82. Lencioni R, Pinto F, Armilotta M, Bartolozzi C. Assessment of tumor vascularity in hepatocellular carcinoma: comparison of power Doppler US and color Doppler US. Radiology 1996;201:353-8.
83. Oliver JH 3rd, Baron RL, Federle MP, Rockette HE Jr. Detecting hepatocellular carcinoma: value of unenhanced or arterial phase CT imaging or both used in conjunction with conventional portal venous phase contrast-enhanced CT imaging. AJR Am J Roentgenol 1996;167:71-7.
84. Baron RL, Oliver JH 3rd, Dodd GD 3rd, Nalesnik M, Holbert BL, Carr B. Hepatocellular carcinoma: evaluation with biphasic, contrast-enhanced, helical CT. Radiology 1996;199:505-11.
85. Stevens WR, Gulino SP, Batts KP, Stephens DH, Johnson CD. Mosaic pattern of hepatocellular carcinoma: histologic basis for a characteristic CT appearance. J Comput Assist Tomogr 1996;20:337-42.
86. Stevens WR, Johnson CD, Stephens DH, Batts KP. CT findings in hepatocellular carcinoma: correlation of tumor characteristics with causative factors, tumor size, and histologic tumor grade. Radiology 1994;191:531-7.
87. Yoshikawa J, Matsui O, Kadoya M, Gabata T, Arai K, Takashima T. Delayed enhancement of fibrotic areas in hepatic masses: CT-pathologic correlation. J Comput Assist Tomogr 1992;16:206-11.
88. Brancatelli G, Baron RL, Peterson MS, Marsh W. Helical CT screening for hepatocellular carcinoma in patients with cirrhosis: frequency and causes of false-positive interpretation. AJR Am J Roentgenol 2003;180:1007-14.
89. Choi BI. The current status of imaging diagnosis of hepatocellular carcinoma. Liver Transpl 2004;10(2 Suppl 1): S20-S25.
90. Szklaruk J, Silverman PM, Charnsangavej C. Imaging in the diagnosis, staging, treatment, and surveillance of hepatocellular carcinoma. AJR Am J Roentgenol 2003; 180:441-54.
91. Oliver JH, Baron RL, Carr BI. CT imaging of hepatocellular carcinoma: CT-arteriography versus trophasic helical contrast CT. Radiology 1997;205:144.
92. Krinsky GA, Lee VS, Theise ND, Weinraub JC, Rofsky NM, Diflo T, et al. Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with MR imaging and explantation. correlation. Radiology 2001;219:445-54.
93. Sadek AG, Mitchell DG, Siegelman ES, Outwater EK, Mateucci T, Hann HW. Early hepatocellular carcinoma that develops within macroregenerative nodules: growth rate depicted at serial MR imaging. Radiology 1995;195: 753-6.
94. Yu JS, Kim MJ. Hepatocellular carcinoma: contrast-enhanced MRI. Abdom Imaging 2002;27:157-67.
95. Liangpunsakul S, Agarwal D, Horlander JC, Kieff B, Chalasani N. Positron emission tomography for detecting occult hepatocellular carcinoma in hepatitis C cirrhotic awaiting liver transplantation. Transplant Proc 2003;35:2995-7.
96. Borzio M, Borzio F, Macchi R, Croce AM, Bruno S, Ferrari A, et al. The evaluation of fine-needle procedures for the diagnosis of focal liver lesions in cirrhosis. J Hepatol 1994;20:117-21.
97. Pitman MB. Fine needle aspiration biopsy of the liver. Principal diagnostic challenges. Clin Lab Med 1998; 18:483-506, vi.
98. Robbins S, Kumar V. Basic pathology. 4th ed. Philadelphia: WB Saunders; 1987. p 598.
99. Inoue K, Takayama T, Higaki T, Watanabe Y, Makuuchi M. Clinical significance of early hepatocellular carcinoma. Liver Transpl 2004;10(2 Suppl 1):S16-S19.
100. Fornari F, Filice C, Rapaccini JL, Caturelli E, Cavanna L, Civardi G, et al. Small (< or =3 cm) hepatic lesions. Results of sonographically guided fine-needle biopsy in 385 patients. Dig Dis Sci 1994;39:2267-75.
101. Caturelli E, Bartolucci F, Biasini E, Vigliotti ML, Andriulli A, Siena DA, et al. Diagnosis of liver nodules observed in chronic liver disease patients during ultrasound screening for early detection of hepatocellular carcinoma. Am J Gastroenterol 2002;97:397-405.
102. Hayashi PH, Trotter JF, Forman L, Kugelmas M, Steinberg T, Russ P, et al. Impact of pretransplant diagnosis of hepatocellular carcinoma on cadaveric liver allocation in the era of MELD. liver Transpl 2004;10:42-8.
103. Caturelli E, Ghittoni G, Roselli P, De Palo M, Anti M. Fine needle biopsy of focal liver lesions: the hepatologist's point of view. Liver Transpl 2004;10(2 Suppl 1):S26-S29.
104. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344:495-500.
105. Huang GT, Sheu JC, Yang PM, Lee HS, Wang TH, Chen DS. Ultrasound-guided cutting biopsy for the diagnosis of hepatocellular carcinoma - a study based on 420 patients. J Hepatol 1996;25:334-8.
106. Durand F, Regimbeau GM, Belghiti J, Sauvanet A, Vilgrain V, Terris B, et al. Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. J Hepatol 2001;35:254-8.
107. Kim SH, Lim HK, Lee WJ, Cho JM, Jang HJ. Needle-tract implantation in hepatocellular carcinoma: frequency and CT findings after biopsy with a 19.5-gauge automated biopsy gun. Abdom Imaging 2000;25:246-50.
108. Ohlsson B, Nilsson J, Strenram U, Akerman M, Tranberg KG. Percutaneous fine-needle aspiration cytology in the diagnosis and management of liver tumours. Br J Surg 2002;89:757-62.
109. Chapoutot C, Perney P, Fabre D, Taourel P, Bruel JM, Larrey D, et al. [Needle-tract seeding after ultrasound-guided puncture of hepatocellular carcinoma. A study of 150 patients]. Gastroenterol Clin Biol 1999;23:552-6 [in French].
110. Yamada N, Shinzawa H, Ukai K, Wakabayashi H, Togashi H, Takahashi T, et al. Subcutaneous seeding of small hepatocellular carcinoma after fine needle aspiration biopsy. J Gastroenterol Hepatol 1993;8:195-8.
111. Bruix J, Sherman M, Lloret JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-30.